Biomarkers have been hailed as a "magic bullet" with the potential to predict disease predisposition, diagnose disease onset and progression, screen for therapy responses and toxicity events, and provide new and novel drug targets. This panel will explore different biomarker classes and evaluate how these biomarkers are influencing the next generation of diagnostics, from early disease detection for cancer to therapy response screening.



Objectives:

Provide clarity to the biomarker maze, and identify key classes of biomarkers that are leading the biomarker field.

Explore the diagnostic potential of these different biomarker classes and how they will shape the diagnostic landscape.

Identify near- and longer-term opportunities in the diagnostic sector.